These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 10571625)

  • 21. Facing up to prostate cancer.
    Ficorelli CT; Weeks B
    Nursing; 2006 May; 36(5):66-8. PubMed ID: 16670611
    [No Abstract]   [Full Text] [Related]  

  • 22. Medical management of advanced prostate cancer: a multidisciplinary team approach.
    Bellmunt Molins J; Gelabert i Mas A
    Expert Rev Anticancer Ther; 2007 Jul; 7(7):977-9. PubMed ID: 17627457
    [No Abstract]   [Full Text] [Related]  

  • 23. Radial distance of extraprostatic extension measured by an ocular micrometer is an independent predictor of prostate-specific antigen recurrence: a new proposal for the substaging of pT3a prostate cancer.
    Epstein JI
    Am J Surg Pathol; 2008 Feb; 32(2):337-8; author reply 338-40. PubMed ID: 18223339
    [No Abstract]   [Full Text] [Related]  

  • 24. Systemic therapeutic strategies for prostate cancer.
    Nelson WG
    Clin Adv Hematol Oncol; 2005 Aug; 3(8):619-21. PubMed ID: 16167046
    [No Abstract]   [Full Text] [Related]  

  • 25. Management of early prostate cancer.
    Stewart A
    Eur J Cancer Care (Engl); 2007 Nov; 16(6):461. PubMed ID: 17944759
    [No Abstract]   [Full Text] [Related]  

  • 26. Prostatic intraepithelial neoplasia and prostate cancer.
    Montironi R; Santinelli A; Mazzucchelli R
    Panminerva Med; 2002 Sep; 44(3):213-20. PubMed ID: 12094135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Can molecular markers stratify the diagnostic value of high-grade prostatic intraepithelial neoplasia?
    Hailemariam S; Vosbeck J; Cathomas G; Zlobec I; Mattarelli G; Eichenberger T; Zellweger T; Bachmann A; Gasser TC; Bubendorf L
    Hum Pathol; 2011 May; 42(5):702-9. PubMed ID: 21237492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of alpha-methylacyl-coA racemase among men with high grade prostatic intraepithelial neoplasia in prostate biopsies.
    Stewart J; Fleshner N; Cole H; Toi A; Sweet J
    J Urol; 2008 May; 179(5):1751-5; discussion 1755. PubMed ID: 18343427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate cancer.
    Schlegel PN
    Curr Ther Endocrinol Metab; 1994; 5():543-50. PubMed ID: 7535663
    [No Abstract]   [Full Text] [Related]  

  • 30. Do prostate specific antigen and prostate specific antigen density enhance the detection of prostate carcinoma after initial diagnosis of prostatic intraepithelial neoplasia without concurrent carcinoma?
    Raviv G; Zlotta AR; Janssen Th; Descamps F; Vanegas JP; Verhest A; Schulman CC
    Cancer; 1996 May; 77(10):2103-8. PubMed ID: 8640677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate cancer in the older man: conflict between tumor biology and medical advancement.
    Cummings JM
    Clin Geriatr Med; 2010 May; 26(2):241-7. PubMed ID: 20497843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AUA issues a policy report on PSA monitoring. The American Urological Association.
    Scott Morey S
    Am Fam Physician; 2000 Aug; 62(4):883-4. PubMed ID: 10969861
    [No Abstract]   [Full Text] [Related]  

  • 33. A 72-year-old man with prostate cancer.
    Crawford ED
    Oncology (Williston Park); 2002 Aug; 16(8):1014-6, 1119-21. PubMed ID: 12201642
    [No Abstract]   [Full Text] [Related]  

  • 34. A guideline to clinical utility of prostate specific antigen.
    Farhat WA; Habbal AA; Khauli RB
    Saudi Med J; 2000 Mar; 21(3):223-7. PubMed ID: 11533789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rising prostate specific antigen after radical prostatectomy: a case based review.
    Nasr R; Goldenberg SL
    Can J Urol; 2001 Aug; 8(4):1306-13. PubMed ID: 11564273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Free and total serum PSA values in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BPH. Is F/T PSA a potential probe for dormant and manifest cancer?
    Tarle M; Kraljić I
    Anticancer Res; 1997; 17(3A):1531-4. PubMed ID: 9179191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Precursors of prostatic cancer: progression, regression and chemoprevention.
    Montironi R; Schulman CC
    Eur Urol; 1996; 30(2):133-7. PubMed ID: 8875193
    [No Abstract]   [Full Text] [Related]  

  • 38. Detection rates of cancer, high grade PIN and atypical lesions suspicious for cancer in the European Randomized Study of Screening for Prostate Cancer.
    Laurila M; van der Kwast T; Bubendorf L; di Lollo S; Pihl CG; Ciatto S; Hugosson J; Määttänen L; Roobol MJ; Kujala PM
    Eur J Cancer; 2010 Nov; 46(17):3068-72. PubMed ID: 21047588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence and pathological characteristics of prostate cancer in Italy: a contribution to the screening debate.
    Picone GM; Pizzi C; Quartuccio A; Scognamiglio G; Tauchmanova L; Di Maio M; Cifarelli P; Contegiacomo A
    Cancer Detect Prev; 2006; 30(5):455-8. PubMed ID: 17067751
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The global state of prostate cancer: new diagnostic tools, minimal requirements for diagnosis and staging, and guidelines in the second millennium.
    Teillac P
    BJU Int; 2004 Dec; 94 Suppl 3():3-4. PubMed ID: 15521882
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.